Category Archives: Mesenchymal Stem Cells

Stem Cell Therapy Market by Treatment Mode Therapeutic Applications - 2020 [196 Slides Report] Stem Cell Therapy Market report categories the Global market by Therapeutic Applications (CNS, CVS, Musculoskeletal, Wound Healing, GIT, Eye, Immune System), Treatment... By: James Evans … Continue reading →

PUBLIC RELEASE DATE: 5-Jun-2014 Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair Putnam Valley, NY. (June 5, 2014) A study by a Korean team of neuroscientists has concluded that when mesenchymal stem cells (MSCs; multipotent structural stem cells capable of differentiation into a variety of cell types) are transplanted into the brains of mice modeled with Alzheimer's disease (AD), the cells stimulate neural cell growth and repair in the hippocampus, a key brain area damaged by AD. The finding could lead to improved AD therapies. The study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-CT1059Oh. Neuroscientists know that Alzheimer's disease is caused by the presence of amyloid-B (AB) "plaques" and "tangles" in the brain's network of neurons. Recently, a protein signaling pathway called "Wnt" (Wingless-type mouse mammary tumor virus (MMTV) related integration site family) which plays a role in embryonic development as well as the development of some diseases, such as cancer, has been linked to Alzheimer's disease. Researchers speculate that an interruption in the Wnt pathway signaling process caused by the AB plaque buildup may have an impact … Continue reading →

A pre-clinical biotech startup that was awarded more than $1 million in state money last year said it has demonstrated that a certain type of abundant stem cells significantly reduce the severity of multiple sclerosis in mice. Farmington's ImStem Biotechnology Inc., which is a member of UConn's technology incubator, said it worked with UConn Health Center scientists and Massachusetts company Advanced Cell Technology Inc. to determine that mesenchymal stem cells (MSCs) derived from human embryonic stem cells are more effective at treating MS in mice than MSCs from the bone marrow of adult donors. In fact, the researchers said they found unexpectedly that the use of adult bone marrow stem cells to treat MS is highly variable and may carry a previously unrecognized risk of poor outcome. The work is published in the June 5 online edition of Stem Cell Reports. ImStem is seeking approvals and investment for Phase 1 clinical trials. See the original post here: Farmington startup treats MS in mice with stem cells … Continue reading →

hES-MSC treat multiple sclerosis mouse Mesenchymal stem cells derived from human embryonic stem cell(hES-MSC) successfully treated multiple sclerosis in a mouse model. Moving mouse are treated with hES-MSC, the paralyzed mice are... By: Xiaofang Wang … Continue reading →

Toronto, Canada (PRWEB) June 04, 2014 Insception Lifebank, Canada's largest cord blood program, now offers expecting parents the option to bank a section of the actual umbilical cord tissue, in addition to banking cord blood. "With exciting developments in stem cell research, scientists continue to identify different types and sources of stem cells that offer therapeutic promise," said Richard Lockie, President and CEO of Insception Lifebank. "The umbilical cord tissue is a rich source of Mesenchymal Stem Cells (MSCs), which are different from the stem cells obtained in cord blood collection." For the past 17 years, Insception Lifebank has focused on umbilical cord blood stem cells, which are used today in the treatment of over 80 life-threatening diseases, and are being investigated in clinical trials involving Autism, Cerebral Palsy, and Pediatric Brain Injury. In contrast, "MSCs can inhibit inflammation, suppress an immune response, aid in tissue repair, and differentiate into structural tissue including bone and cartilage," explains Dr. Ian Rogers of the Lunenfeld-Tanenbaum Research Institute. Because of their versatility, MSCs are being investigated to treat a variety of therapeutic areas including Heart Failure, Stroke, Rheumatoid Arthritis, Multiple Sclerosis and many more. The application of cord tissue MSCs is in the … Continue reading →

PUBLIC RELEASE DATE: 3-Jun-2014 Contact: Sandra Hutchinson s3.hutchinson@qut.edu.au 61-731-389-449 Queensland University of Technology A QUT scientist is hoping to unlock the potential of stem cells as a way of repairing neural damage to the brain. Rachel Okolicsanyi, from the Genomics Research Centre at QUT's Institute of Health and Biomedical Innovation, said unlike other cells in the body which were able to divide and replicate, once most types of brain cells died, the damage was deemed irreversible. Ms Okolicsanyi is manipulating adult stem cells from bone marrow to produce a population of cells that can be used to treat brain damage. "My research is a step in proving that stem cells taken from the bone marrow can be manipulated into neural cells, or precursor cells that have the potential to replace, repair or treat brain damage," she said. Ms Okolicsanyi's research has been published in Developmental Biology journal, and outlines the potential stem cells have for brain damage repair. "What I am looking at is whether or not stem cells from the bone marrow have the potential to differentiate or mature into neural cells," she said. "Neural cells are those cells from the brain that make everything from the structure of … Continue reading →

PUBLIC RELEASE DATE: 4-Jun-2014 Contact: Ainhoa Iriberri airiberri@cnic.es 34-610-295-556 Centro Nacional de Investigaciones Cardiovasculares Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Centro Nacional de Investigaciones Oncolgicas (CNIO) have succeeded in reproducing, in human cells, the chromosomal translocations that cause two types of cancer: acute myeloid leukemia and Ewing's sarcoma. The findings, published today in Nature Communications, open the way to the development of new therapeutic targets for the treatment of these cancers. The study was led by Juan Carlos Ramrez and Ral Torres, of the CNIC Viral Vectors Unit, and Sandra Rodrguez-Perales, of the Molecular Cytogenetics group at the CNIO, directed by Juan Cruz Cigudosa. The research team used innovative technology to demonstrate that it is possible to reproduce chromosomal modifications in human cells that are identical to the modifications observed in leukemias and other types of cancer. The new technology, which uses molecular tools to manipulate the genome, has two main advantages. First, it allows researchers to generate previously unavailable cell models for the study of tumor biology. And second, future development will allow the study of new therapeutic targets and therapies. The development of tumors is caused by multiple changes in cell physiology and … Continue reading →

(2006-06) David Steenblock - Umbilical Cord Stem Cell Therapy David Steenblock Umbilical cord stem cell therapy 2006-06-15 Visit the Silicon Valley Health Institute (aka Smart Life Forum) at http://www.svhi.com Silicon Valley Health Institute Smart... By: Silicon Valley Health Institute … Continue reading →

Reprogramming Leukocytes to Mesenchymal Stem Cells Via Retrodifferentiation Time lapse imaging of human leukocytes conversion into Pluripotent Mesenchymal stem cells via a process of retrodifferentiation / dedifferentiation and subsequent transdifferentiation into... By: Ilham Abuljadayel … Continue reading →

Miami (PRWEB) May 30, 2014 GlobalStemCellsGroup.com will host the First International Symposium on Stem Cell Research in Buenos Aires, Argentina Oct. 2, 3 and 4. The symposium will provide an opportunity to showcase advancements in stem cell research and therapies on a global level and establish a dialogue among the worlds leading stem cell experts. Pioneers and luminaries in stem cell medicine will be featured speakers as well as accomplished guests prepared to share their knowledge and experience in their individual medical specialties. Regenerative medicine as a field is still in its infancy, and Global Stem Cells Group President and CEO Benito Novas believes it is time to clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing. The first step, Novas says, is establishing a dialogue between researchers and practitioners in order to move stem cell therapies from the lab to the physicians office. Our objective is to open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices, Novas says. Our mission is to bring the benefits of … Continue reading →